<DOC>
	<DOC>NCT02151123</DOC>
	<brief_summary>The specific aim of the study is to determine the false negative rate of the Metabiomics Colon Polyp and Colorectal Cancer Assay for Cancer.</brief_summary>
	<brief_title>Metabiomics Colon Cancer Clinical Research Study</brief_title>
	<detailed_description>The purpose of this study is to conduct clinical research to investigate the association of the gut microbiome with colonic neoplasia. In this case several types of gut microbiome samples will be collected from patients undergoing colectomy for colonic adenocarcinoma; those samples will be tested by Metabiomics Colon Polyp and Colorectal Cancer Assay and the percentage of false negative (test returns a negative for cancer) results determined.</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<criteria>Recently diagnosed with colorectal cancer (CRC) and scheduled for colectomy Male or female, Age: 1895 years, Able to comprehend, sign, and date the written informed consent form (ICF), Able to give informed consent in English Women and minorities will be included. History of Inflammatory Bowel Disease Antibiotics within 2 weeks of sample collection. Colonoscopy, colon prep or bowel contrast agent within 7 days prior to sample collection Any radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Colonic Neoplasms</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Microbiome</keyword>
</DOC>